fingolimod hydrochloride has been researched along with ponesimod in 4 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (ponesimod) | Trials (ponesimod) | Recent Studies (post-2010) (ponesimod) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 62 | 19 | 61 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | ponesimod (IC50) |
|---|---|---|---|
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | 0.0126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bieberich, E; Bryant, L; Chen, C; Chen, Z; Cuzzocrea, S; Doyle, T; Esposito, E; Janes, K; Kamocki, K; Li, C; Little, JW; Neumann, WL; Nicol, G; Obeid, L; Petrache, I; Salvemini, D; Snider, A | 1 |
| Sadik, CD; Thieme, M; Zillikens, D | 1 |
| Chaudhry, BZ; Cohen, JA; Conway, DS | 1 |
| Cohen, JA; McGinley, MP | 1 |
3 review(s) available for fingolimod hydrochloride and ponesimod
| Article | Year |
|---|---|
Sphingosine-1-phosphate modulators in inflammatory skin diseases - lining up for clinical translation.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Receptors, Lymphocyte Homing; Receptors, Lysophospholipid; Skin Diseases; Sphingosine; Thiazoles | 2017 |
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indans; Indoles; Multiple Sclerosis; Naphthalenes; Oxadiazoles; Propanolamines; Receptors, Lysosphingolipid; Thiazoles; Treatment Outcome | 2017 |
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System Diseases; Indans; Multiple Sclerosis; Nervous System Diseases; Oxadiazoles; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles | 2021 |
1 other study(ies) available for fingolimod hydrochloride and ponesimod
| Article | Year |
|---|---|
The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.
Topics: Anilides; Animals; Antineoplastic Agents, Phytogenic; Cytokines; Enzyme Activation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Indans; Lysophospholipids; Male; Neuralgia; Organophosphonates; Oxadiazoles; Paclitaxel; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazoles; Thiophenes | 2014 |